---
title: "GridAI Technologies Corp. 1Q 2026: Revenue $38K, EPS ($0.82) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287752542.md"
description: "GridAI Technologies Corp. reported Q1 2026 revenue of $38K, a significant increase from $0 in Q1 2025, but a net loss of $3.63M compared to a loss of $1.34M a year earlier. Diluted EPS was ($0.82), slightly improved from ($0.84). The company is focusing on AI-driven energy services post-acquisition of Grid AI/AMPX, while discontinuing several biopharma programs and prioritizing operational scaling and strategic financing."
datetime: "2026-05-27T10:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287752542.md)
  - [en](https://longbridge.com/en/news/287752542.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287752542.md)
---

# GridAI Technologies Corp. 1Q 2026: Revenue $38K, EPS ($0.82) — 10-Q Summary

GridAI Technologies Corp. reported first-quarter 2026 results reflecting the company's shift into AI-driven energy services after completing the Grid AI/AMPX acquisition, with revenue of $38K and a widened net loss versus the year-ago quarter.

**Financial Highlights**

-   Revenue was $38K for Q1 2026, compared with $0 in Q1 2025.
-   Net income (loss applicable to common shareholders) was a loss of $3.63M for Q1 2026, compared with a loss of $1.34M in Q1 2025.
-   Diluted EPS — basic and diluted — was a loss of ($0.82) for Q1 2026, versus ($0.84) for Q1 2025.

**Business Highlights**

-   Revenue Growth & Channel Shift: The company recognized $38K of revenue in Q1 2026 driven by Grid AI/AMPX energy services following the September 2025 acquisition, marking a strategic shift toward AI energy revenue.
-   Product & Pipeline Focus: GridAI retained Adrulipase as its sole biopharma program and discontinued Latiglutenase, CypCel, Capeserod and Niclosamide programs.
-   Operational Integration: Management completed integration of Grid AI and AMPX operations, with increased R&D and G&A spending to support development of the energy platform.
-   Commercial Momentum: Early-stage commercial activity in grid-edge software and services has begun, with associated cost of services and platform development reflecting go-to-market efforts.
-   Forward Priorities: Management is prioritizing scaling Grid AI/AMPX operations, advancing Adrulipase only as capital allows, and pursuing strategic financing.

Original SEC Filing: GridAI Technologies Corp. \[ GRDX \] - 10-Q - May. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GRDX.US](https://longbridge.com/en/quote/GRDX.US.md)

## Related News & Research

- [Goldman Sachs Says This 1 Stock Is Set to Be the Biggest AI Productivity Winner](https://longbridge.com/en/news/296259340.md)
- [Forum Energy Technologies CFO to present at EnerCom Denver energy investment conference](https://longbridge.com/en/news/295706044.md)
- [14:46 ETUniversity of Phoenix student survey points to responsible use, judgment and real-world practice as foundations of AI readiness](https://longbridge.com/en/news/296260376.md)
- [DXC study shows 80% of DACH firms insist on human oversight of new AI processes](https://longbridge.com/en/news/296190696.md)
- [AI agent security must move beyond human-in-the-loop, experts say](https://longbridge.com/en/news/296269444.md)